Read + Share
Moik F, Riedl JM, Ay C. Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in
EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary
results from the phase III MARIPOSA-2 study. Ann Oncol 2024;35:327.
PMID: 38092622
|
 |
|
